Situation
A global pharmaceutical company wanted to better understand the impact of its patient access programs, which Axios had been implementing across markets for several years. While the company knew how many patients its programs had reached, it wanted to understand the bigger picture.
How many patients could potentially benefit from treatment, and what proportion of those patients were actually being reached?
The company also wanted to understand the socioeconomic profile of patients accessing its programs and whether the programs were reaching those patients facing the greatest affordability barriers.
Solution
Axios combined real-world evidence from its patient access programs with theoretical estimates of the patient pool to develop a measure of access depth. Axios:
- Estimated the total potential patient population in each market and compared this with the number of patients actually reached through the access programs.
- Segmented the patients reached by income level to understand the socioeconomic profile of program participants.
This allowed Axios to look beyond enrollment numbers and assess the depth of access being achieved in each market, providing a clearer picture of both program reach and the patients being served.
Results
The analysis enabled the company to understand how effectively its access programs were reaching the potential patient population across markets.
It provided insight into which income segments were being reached and whether programs were successfully reaching patients with greater financial barriers to treatment.
The findings gave the company a more complete view of the reach, equity, and impact of its access programs, providing evidence to inform future program strategy and opportunities to expand patient access.
